Novavax (NVAX) closed the most recent trading day at $8.88, moving 1.66% from the previous trading session.
Novavax has transferred commercialization of its COVID-19 vaccine in Europe to Sanofi. The company is shifting focus to monetizing its Matrix-M adjuvant through partnerships and licensing. These moves
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to signific
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed that advisers to the U.S. Food and Drug Administration (FDA) will weigh upd
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax has had an impressive run over the past six months as its shares have beaten the S&P 500 by 27.6%. The stock now trades at $9.21, marking a 37.6% gain. This was partly due to its solid quarter
View interactive chart, options flow, and AI analysis for NVAX on Zorveq Finance.
Open NVAX Chart & Analysis →